Share on StockTwits

Regeneron Pharmaceuticals (NASDAQ:REGN) major shareholder Sanofi bought 356,700 shares of the stock on the open market in a transaction dated Monday, July 7th. The shares were purchased at an average price of $312.37 per share, with a total value of $111,422,379.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) traded down 0.34% on Tuesday, hitting $310.52. 1,045,562 shares of the company’s stock traded hands. Regeneron Pharmaceuticals has a 52 week low of $227.64 and a 52 week high of $352.49. The stock’s 50-day moving average is $300.9 and its 200-day moving average is $301.1. The company has a market cap of $30.651 billion and a price-to-earnings ratio of 89.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings results on Thursday, May 8th. The company reported $0.58 EPS for the quarter, missing the Thomson Reuters consensus estimate of $0.94 by $0.36. The company had revenue of $626.00 million for the quarter, compared to the consensus estimate of $609.04 million. During the same quarter in the prior year, the company posted $1.78 earnings per share. The company’s quarterly revenue was up 42.3% on a year-over-year basis. Analysts expect that Regeneron Pharmaceuticals will post $9.90 EPS for the current fiscal year.

A number of analysts have recently weighed in on REGN shares. Analysts at Zacks upgraded shares of Regeneron Pharmaceuticals from a “neutral” rating to an “outperform” rating in a research note on Wednesday, June 25th. They now have a $334.00 price target on the stock. Separately, analysts at Goldman Sachs reiterated a “buy” rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, June 24th. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus price target of $344.00.

Regeneron Pharmaceuticals, Inc (NASDAQ:REGN) is an integrated biopharmaceutical company, which discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.